MERCK KGAA

A Norwegian observational study of 285 RRMS patients found rituximab demonstrated superior disease control compared to cladribine, with only 17% showing new MRI activity versus 57% for cladribine over 4 years.

Merck KGaA, Darmstadt, Germany has entered a strategic collaboration with Skyhawk Therapeutics valued at over $2 billion to discover novel RNA-targeting small molecules for neurological disorders with high unmet medical need.

RESTEM, a clinical-stage biotech company, received FDA Orphan Drug Designation in December 2024 for its umbilical cord outer lining stem cell program targeting polymyositis and dermatomyositis.

MilliporeSigma and Washington University in St. Louis have signed a memorandum of understanding to expand their nearly century-long collaboration, focusing on joint research initiatives and technology development.

Simtra BioPharma Solutions has completed construction of a new 1,800 square meter production facility at its Halle, Germany campus, expanding total production area to nearly 12,000 square meters.

The BRACELET-1 trial demonstrated that pelareorep combined with paclitaxel achieved a 31% objective response rate and 12.1-month median progression-free survival in HR+ HER2- metastatic breast cancer patients.

Simtra BioPharma Solutions and MilliporeSigma have established a five-year strategic alliance to create a turnkey offering for antibody-drug conjugate manufacturing and bioconjugation services.

Biocytogen Pharmaceuticals has received a Japan Patent Office invention patent for its RenMab fully human antibody mouse platform technology, marking a significant milestone in global intellectual property expansion.

Merck KGaA's antibody-drug conjugate precemtabart tocentecan demonstrated safety and tolerability in a Phase Ib trial for metastatic colorectal cancer patients.

Pimicotinib demonstrated a statistically significant 54.0% objective response rate versus 3.2% for placebo in the global Phase 3 MANEUVER trial for tenosynovial giant cell tumor.